Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
PolyPid ( (PYPD) ) has provided an update.
On May 14, 2025, PolyPid Ltd. announced the successful completion of patient enrollment in the Phase 3 SHIELD II trial of D-PLEX100, aimed at preventing abdominal colorectal surgical site infections. The company anticipates releasing top-line results by the end of the second quarter of 2025, which could significantly impact its market position. PolyPid is preparing for regulatory submissions in 2026, leveraging its Fast Track and Breakthrough Therapy designations, and is advancing commercialization and partnership discussions in the U.S. The company’s financial results for the first quarter of 2025 showed increased R&D expenses due to the SHIELD II trial, with a net loss of $8.3 million. PolyPid’s cash reserves are expected to fund operations into the third quarter of 2025, with potential additional funding from warrant exercises.
The most recent analyst rating on (PYPD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on enhancing surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the local, controlled, and prolonged release of therapeutics, with their lead product candidate, D-PLEX100, in Phase 3 trials for preventing abdominal colorectal surgical site infections. The company is also exploring the efficacy of OncoPLEX for treating solid tumors, starting with glioblastoma.
Average Trading Volume: 14,167
Technical Sentiment Signal: Sell
Current Market Cap: $29.04M
Learn more about PYPD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue